Questions & Answers with Rose Loughlin
February 11, 2022
Moderna People Profile
As we celebrated International Day of Women and Girls in Science, we caught up with our colleague Rose Loughlin, who leads Research and Early Development at Moderna.
Rose talks about uncomfortable opportunities to learn, leaving the ladder down, and shamelessly asking a lot of questions.
Moderna 2021 Shareholder Letter
January 4, 2022
By Stéphane Bancel, Chief Executive Officer
Dear fellow shareholders,
2021 was a year of monumental impact and change for Moderna. After a decade of pioneering the development of our mRNA platform, we were ready and well-positioned to play a critical role in combatting the COVID-19 pandemic globally with our mRNA vaccine.
Our COVID-19 vaccine has been granted emergency use authorization (EUA) or emergency use listing by the World Health Organization (WHO) and health agencies in more than 60 countries, to which we shipped approximately 800 million doses in 2021. This was no small task for a team of 2,700 people.
Questions & Answers with Carlos Peralta
December 21, 2021
Moderna People Profile
The importance of data and growth of analytics and AI in biotech is clear, and Moderna strives to be on the leading edge as we continue to grow. For an insider’s view of this, we caught up with our colleague Carlos Peralta, a member of Moderna’s Informatics team.
Carlos talks about what attracted him to his first role in biotech (at Moderna), his sources of inspiration, and what makes for a good work/life balance
Moderna Launches AI Academy for All Employees
December 09, 2021
By Dave Johnson, Chief Data & Artificial Intelligence Officer, Moderna
We have several “Mindsets” at Moderna that define how we work, make decisions and build the best version of our company. Two of these Mindsets are “obsess over learning” and “digitize everywhere possible.” They come together like a well-fit jigsaw puzzle with the introduction of our Artificial Intelligence (AI) Academy, an immersive learning experience for all Moderna employees.
Positive Progress in mRNA Use for Cardiovascular Disease
November 15, 2021
By Ruchira Glaser, SVP and Therapeutic Area Head of Rare Diseases, Cardiovascular Disease and Autoimmune Diseases
Paul Burton, Chief Medical Officer
What if mRNA could treat life-threatening cardiovascular diseases such as heart failure?
Moderna and AstraZeneca are collaborating on a locally administered mRNA therapeutic (AZD8601) that encodes for vascular endothelial growth factor-A (VEGF-A) to promote recovery of cardiac function through tissue regeneration. Importantly, it is directly delivered into the myocardium—the muscular middle layer of the wall of the heart—to produce the VEGF-A protein in a specific place.